FDA May Modify Or Halt Review Of Warning Letters By Office Of Chief Counsel
This article was originally published in The Gray Sheet
FDA is reexamining the role that its Office of Chief Counsel (OCC) plays in the review of warning letters that include quality system violations
You may also be interested in...
FDA Commissioner Margaret Hamburg is honing the agency's enforcement system to get warning letters out faster and create a formal "close-out" process that publicly indicates when a firm has addressed FDA's concerns
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.